- Home
- BLW vs MNPR Comparison
BLW vs MNPR Comparison
Compare BLW & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLW | MNPR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.4M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLW | MNPR |
|---|---|---|
| Price | $13.97 | $86.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $97.83 |
| AVG Volume (30 Days) | 85.9K | ★ 160.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.35 | $19.87 |
| 52 Week High | $14.26 | $105.00 |
Technical Indicators
Market Signals| Indicator | BLW | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 51.97 |
| Support Level | $13.64 | $83.86 |
| Resistance Level | $13.86 | $100.50 |
| Average True Range (ATR) | 0.12 | 7.88 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 65.22 | 40.97 |
Price Performance
Historical ComparisonAbout BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.